Emter CA, Henze M, DuVall M, Lehman S, Lee L, Barthel B, Hawryluk NA, Madden M, Wu Y, Perry A, Beyer M, Wei E, Rupert C, Roof S, Peter A, DiNatale E, Cantrell S, Tolley J, Schlachter S, van der Velden J, Michels M, Seidman C, Ma W, Leinwand L, Campbell S, Ochala J, Bluemke D, Tharp D, Seidman J, Del Rio CL, Semigran M, Evanchik M, Koch K, Russell A. Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator. JCI Insight. 2026 Sep 22; 11(18).

Peter JA, Weiser TA, Niswander LA, Batey RT, Wuttke DS. MeCP2 MBD-ID module: a unified DNA/RNA binding interface disrupted in Rett syndrome. Nucleic Acids Res. 2026 Sep 22; 54(18).

Boslough M, Taylor MRG, Mestroni L, Lombardi R. Genetic Dilated Cardiomyopathy: A Review. Methodist Debakey Cardiovasc J. 2026; 22(4):68-77.

Pointer MD, Nash WJ, Gage MJG, Chapman T, Maklakov AA, Richardson DS. Sexual selection purges mutation load, but not overall genetic diversity, decreasing vulnerability to extinction. Proc Natl Acad Sci U S A. 2026 Sep 15; 123(37):e2608675123.

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep; 27(9):1094-1109.

Slater BA, Muth E, Meeks NJL. The First Case of Isolated Uterine Atony as the Only Symptom in an Individual With ACTG2-Associated Visceral Myopathy. Clin Genet. 2026 11; 110(5):637-638.

Teklemariam TA, Finnerty RM, Coats JB, Nelson SW. Basic-patch mutations in bacteriophage T4 Rad50 uncouple ATPase activation from processive nuclease activity. Biosci Rep. 2026 Aug 19; 46(8).

Shulman DS, Vo KT, Balis FM, Lindsay H, DeNardo BD, Place AE, Chi SN, Kamihara J, O'Neill AF, Church AJ, Crompton BD, Klega K, Tanhaemami M, Armant M, Pikman Y, Stegmaier K, Ezrre S, Czaplinski J, Walensky LD, Annis DA, Bhushan K, Kao PC, London WB, DuBois SG. A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies. Clin Cancer Res. 2026 Aug 14; 32(16):3466-3475.

Espinoza-Gutarra MR, Jarret B, Wang X, Afghahi A, Bae S. Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2. Cancer Rep (Hoboken). 2026 08; 9(8):e70657.

Phillips WJ, Leong R, Yeung B, Al Lawati A, Camidge DR, Lo B, Wheatley-Price P. The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC. Curr Oncol. 2026 Jul 23; 33(8).